The science and politics of the new mRNA flu vaccine
Summary
Dr. Anna Durbin discusses the first season of the mRNA flu vaccine, noting it uses the same strains as traditional vaccines due to regulatory timelines. She explains that side effects like fever stem from the lipid nanoparticle delivery system and highlights how the dissolution of the ACIP committee has complicated insurance coverage. Durbin also warns that reduced U.S. investment in mRNA technology risks falling behind global competitors in future pandemic preparedness.
Topics discussed
Sponsors: Common Sense Media, Poster House, and The Met
Introduction to the mRNA flu vaccine and Dr. Anna Durbin
Strain selection timing and the promise of faster mRNA production
FDA and WHO meetings on strain selection and bureaucratic delays
Surveillance systems and evaluating vaccine effectiveness this season
Impact of ACIP dissolution on insurance coverage and recommendations
Side effects comparison: mRNA lipid nanoparticles vs. traditional alum
Managing side effects and accessing the vaccine at pharmacies
Insurance coverage challenges and out-of-pocket costs
Global adoption of mRNA technology and US investment concerns
Public health risks of falling behind in mRNA vaccine development
Closing remarks and production credits
Sponsor: Poster House museum
Listen ad-free on Castria